GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » Cash Flow from Financing

SQI Diagnostics (SQI Diagnostics) Cash Flow from Financing : $3.85 Mil (TTM As of Mar. 2023)


View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2023, SQI Diagnostics received $0.02 Mil more from issuing new shares than it paid to buy back shares. It received $0.33 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.18 Mil on other financial activities. In all, SQI Diagnostics earned $0.52 Mil on financial activities for the three months ended in Mar. 2023.


SQI Diagnostics Cash Flow from Financing Historical Data

The historical data trend for SQI Diagnostics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Cash Flow from Financing Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 5.19 4.76 7.86 12.26

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.88 3.12 -0.57 0.78 0.52

SQI Diagnostics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

SQI Diagnostics's Cash from Financing for the fiscal year that ended in Sep. 2022 is calculated as:

SQI Diagnostics's Cash from Financing for the quarter that ended in Mar. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SQI Diagnostics  (OTCPK:SQIDF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

SQI Diagnostics's issuance of stock for the three months ended in Mar. 2023 was $0.02 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

SQI Diagnostics's repurchase of stock for the three months ended in Mar. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

SQI Diagnostics's net issuance of debt for the three months ended in Mar. 2023 was $0.33 Mil. SQI Diagnostics received $0.33 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

SQI Diagnostics's net issuance of preferred for the three months ended in Mar. 2023 was $0.00 Mil. SQI Diagnostics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

SQI Diagnostics's cash flow for dividends for the three months ended in Mar. 2023 was $0.00 Mil. SQI Diagnostics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

SQI Diagnostics's other financing for the three months ended in Mar. 2023 was $0.18 Mil. SQI Diagnostics received $0.18 Mil on other financial activities.


SQI Diagnostics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (SQI Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (SQI Diagnostics) Headlines